Tomita N, Inoue S, Ikeda S. Applicability of HTA in policy decision-making: Part I. J Health Care Community. 2011;21(2):163-174. (in Japanese)

Iwata N, Ohnishi K, Inoue S. Comparison between the treatment outcomes of monotherapy with new antipsychotic drugs using medical fee receipts. Jap J Clin Psychopharmacol. 2011;14(8):1387-1395. (in Japanese)

Ikeda S, Ogawa S, Hosokawa T, Murakawa K, Hotta N, Nonno S, Takahashi K, Kikuchi S, Hanaoka K, Kobayashi M. Cost-effectiveness analysis of pregabalin for treatment of peripheral neuropathic pain. Jpn JPharmacoepidemiol. 2011;16(1):1-9. (in Japanese)

Kobayashi M. Pharmacoeconomics and software. The Operations Research. 2003;48(5):359-365. (in Japanese)

Nakahara N,Kobayashi M, Mano T, Nakamura J. System Dynamics Simulation for Acute Schizophrenia Treatment. ISPOR 15th Annual International Meeting, 18 May, 2010, Atlanta, GA, USA. (Poster presentation)

Kobayashi M. The essence of pharmacoeconomics[39] ISPOR 16th Annual International Meeting. Monthly Medical Information Express. 2011;6:90-93. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[38] Pharmacoeconomic evaluation of cancer: (6) Myelodysplastic syndromes (MDS). Monthly Medical Information Express. 2011;6:90-93. (in Japanese)

Kobayashi M. The essence of pharmacoeconomics[37] Pharmacoeconomic evaluation of cancer: (5) Breast cancer. Monthly Medical Information Express. 2011;5:88-91. (in Japanese)

Kobayashi M. "Medical risk and quantitative approach." Medical risk management. Mano T, ed. Japan Medical Publisher, 2006, p.23-45. (in Japanese)